13F Filings History of Ghost Tree Capital, LLC
- Latest 13F filing
- Q3 2024 - 14 Nov 2024
- Latest reported 13F value
- $293,215,532
- Largest 13F holdings
-
BIOHAVEN LTD SRPT NVO BPMC AXSM TARS CATX CGON ROIV PCVX VKTX SNDX
+8 more
JANX ASND CRNX SLNO TGTX RZLT PHAT MLTX - Form 13F summary
-
- Ghost Tree Capital, LLC Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- Ghost Tree Capital, LLC reported 51 equity holdings with a total reported market value of $293,215,532 for Q3 2024. Top reported holdings included BIOHAVEN LTD, SRPT, NVO, BPMC, and AXSM.
- Manager signature
- Matthew James Diaz - CHIEF COMPLIANCE OFFICER
- Manager location
- New York, NY
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Ghost Tree Capital, LLC with Pro and return when a new 13F portfolio filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
Holdings Value
Form 13F evidence
Quarterly portfolio filings
SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.
Latest quarter
Q3 2024
Latest value
$293,215,532
Quarter delta
+$5,863,790
Accepted
14 Nov 2024, 09:13
Rows shown
1-25 of 44
| Quarter | Holdings | SEC-reported value | Bought | Sold | Net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q3 2024 | 51 | $293,215,532 | +$91,978,483 | -$116,887,489 | -$24,909,006 | BIOHAVEN LTD, SRPT, NVO, BPMC, AXSM | 13F-HR | 14 Nov 2024, 09:13 |
| Q2 2024 | 59 | $287,351,742 | +$97,428,587 | -$102,113,553 | -$4,684,966 | BHVN, MLTX, SLNO, AXSM, ASND | 13F-HR | 14 Aug 2024, 11:40 |
| Q1 2024 | 65 | $311,055,173 | +$165,143,430 | -$43,523,860 | +$121,619,570 | AXSM, SRPT, BHVN, MLTX, ROIV | 13F-HR | 15 May 2024, 09:18 |
| Q4 2023 | 44 | $173,719,342 | +$77,992,378 | -$143,533,988 | -$65,541,610 | AXSM, BHVN, SRPT, AMAM, ROIV | 13F-HR | 14 Feb 2024, 08:13 |
| Q3 2023 | 58 | $206,522,308 | +$69,592,516 | -$97,483,087 | -$27,890,571 | MLTX, KRYS, MDGL, TGTX, ASND | 13F-HR | 14 Nov 2023, 08:44 |
| Q2 2023 | 55 | $277,094,110 | +$69,412,408 | -$74,047,841 | -$4,635,433 | TGTX, MLTX, AKRO, APLS, PCVX | 13F-HR | 14 Aug 2023, 08:30 |
| Q1 2023 | 52 | $264,323,000 | +$120,485,981 | -$103,607,149 | +$16,878,832 | TGTX, AMLX, AXSM, ASND, APLS | 13F-HR | 15 May 2023, 08:42 |
| Q4 2022 | 35 | $234,221,000 | +$60,221,077 | -$103,090,656 | -$42,869,579 | RETA, AXSM, ASND, APLS, QQQ | 13F-HR | 14 Feb 2023, 08:44 |
| Q3 2022 | 35 | $242,830,096 | +$99,670,920 | -$41,838,385 | +$57,832,535 | APLS, RETA, RLMD, AMLX, AXSM | 13F-HR | 14 Nov 2022, 08:33 |
| Q2 2022 | 29 | $145,457,000 | +$40,527,251 | -$75,133,087 | -$34,605,836 | FOLD, APLS, SRPT, AXSM, COGT | 13F-HR | 15 Aug 2022, 12:08 |
| Q1 2022 | 39 | $201,810,000 | +$38,053,766 | -$63,952,101 | -$25,898,335 | ASND, COGT, APLS, MRUS, FOLD | 13F-HR | 16 May 2022, 08:05 |
| Q4 2021 | 43 | $261,124,000 | +$82,643,951 | -$129,219,080 | -$46,575,129 | ASND, APLS, COGT, CLDX, RAPT | 13F-HR | 16 Feb 2022, 12:37 |
| Q3 2021 | 55 | $303,305,000 | +$86,588,647 | -$107,989,737 | -$21,401,090 | ASND, IOVA, CLDX, COGT, ARVN | 13F-HR | 15 Nov 2021, 11:34 |
| Q2 2021 | 49 | $319,790,000 | +$69,401,525 | -$90,428,013 | -$21,026,488 | RAPT, ASND, FATE, XENE, ARVN | 13F-HR | 10 Aug 2021, 18:54 |
| Q1 2021 | 46 | $356,848,000 | +$88,699,590 | -$86,795,567 | +$1,904,023 | SNDX, TRILLIUM THERAPEUTICS INC, ASND, KURA, IOVA | Restatement | 10 Aug 2021, 18:44 |
| Q4 2020 | 40 | $402,764,000 | +$121,452,602 | -$114,000,878 | +$7,451,724 | SNDX, TRILLIUM THERAPEUTICS INC, RCKT, IOVA, APLS | Restatement | 17 Feb 2021, 18:29 |
| Q3 2020 | 45 | $295,733,000 | +$94,443,830 | -$95,696,422 | -$1,252,592 | TRILLIUM THERAPEUTICS INC, ASND, MRSN, IOVA, IMVT | 13F-HR | 16 Nov 2020, 06:18 |
| Q2 2020 | 39 | $303,413,000 | +$73,774,694 | -$124,436,123 | -$50,661,429 | IMMU, CNST, ADVM, MRTX, IOVA | 13F-HR | 14 Aug 2020, 07:14 |
| Q1 2020 | 42 | $226,606,000 | +$56,946,770 | -$131,122,174 | -$74,175,404 | CNST, ASND, IMMU, ADVM, AXSM | 13F-HR | 15 May 2020, 08:25 |
| Q4 2019 | 45 | $370,469,000 | +$154,233,190 | -$216,829,302 | -$62,596,112 | ASND, CNST, AXSM, MRTX, IOVA | Restatement | 09 Apr 2020, 13:16 |
| Q3 2019 | 39 | $287,102,000 | +$106,229,496 | -$125,807,707 | -$19,578,211 | BPMC, MRTX, SRPT, SAGE, BHVN | Restatement | 09 Apr 2020, 13:03 |
| Q2 2019 | 39 | $383,336,000 | +$152,286,479 | -$136,675,992 | +$15,610,487 | SRPT, BPMC, MRTX, ASND, AXSM | Restatement | 09 Apr 2020, 13:01 |
| Q1 2019 | 37 | $351,978,000 | +$173,814,052 | -$77,383,911 | +$96,430,141 | ASND, ACAD, BPMC, FOLD, GBT | Restatement | 09 Apr 2020, 12:58 |
| Q4 2018 | 35 | $203,049,000 | +$67,244,543 | -$192,891,812 | -$125,647,269 | MRTX, DRNA, VRTX, IMMU, RTRX | Restatement | 08 Apr 2020, 20:10 |
| Q3 2018 | 50 | $387,944,000 | +$141,808,643 | -$100,970,132 | +$40,838,511 | SRPT, PTCT, MRTX, ECYT, IMMU | Restatement | 08 Apr 2020, 20:17 |